PsychedelicNewsBreaks Archive - Page 33 of 69

ThursdayJan 13, 2022 12:38 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Eyes Strong Outlook for Growth and Profitability

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today issued a corporate update. Among the highlights, Delic reported that it has 12 strategically located and operational clinics with 15 more opening in the next 18 months. “There are 51.5 million Americans who have experienced a mental health condition and the ongoing pandemic has only exacerbated the crisis,” said Matt Stang, co-founder and CEO of Delic. “We are seeing a strong demand for alternatives to current treatments with lasting outcomes and less side effects. At Delic, we have built the…

ThursdayJan 13, 2022 11:28 am

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Launches Canadian Program to Support Psychedelic-Assisted Psychotherapy

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has unveiled its Special Access Support and Supply Program (“SASSP”). The program provides products, services and support to hospitals, clinics and physicians in Canada who utilize psychedelic-assisted psychotherapy treatment. Health Canada recently added psilocybin and MDMA to its approved list of substances in its Special Access Program (“SAP”), creating an opportunity for MYCOF to provide critical resources in helping thousands of healthcare professionals and clinics offer these treatments to those in need. The Health Canada announcement allows…

TuesdayJan 11, 2022 1:27 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Featured in Latest Episode of Bell2Bell Podcast

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, was featured in the Bell2Bell Podcast, a part of IBN’s (“InvestorBrandNetwork”) sustained effort to provide specialized content distribution via widespread syndication channels. Mydecine’s co-founder, chairman and CEO Josh Bartch joined the latest episode to discuss the company’s business model, highlighting its phased approach to developing improved treatment options for a variety of underserved indications. “Mydecine Innovations Group… is really focused on first- and second-generation novel therapeutics derived from different psychedelic molecules. We’re using those as a…

TuesdayJan 11, 2022 12:35 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC Opens Salt Lake City Clinic

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that its subsidiary, Ketamine Wellness Centers (“KWC”), has officially expanded operations into Utah with the opening of its Salt Lake City location. Acquired by Delic in September 2021, KWC currently operates 11 ketamine infusion treatment clinics across nine states, delivering more than 61,000 treatments to date. “Utah currently experiences one of the highest rates of mental health concerns in the country with lower access to care, and KWC aims to serve this new community of patients struggling with treatment-resistant…

TuesdayJan 11, 2022 12:28 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures IRB Approval for Feasibility Study Using Kernel’s Quantitative Neuroimaging Technology

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that an Institutional Review Board (“IRB”) has approved a company-sponsored feasibility study. The study will use Kernel’s quantitative neuroimaging technology, Kernel Flow, to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. As part of its sponsorship of the feasibility study, Cybin will retain an exclusive interest in any innovations discovered or developed through its independent analysis of the findings. “By leveraging the Kernel Flow technology, we may have the ability to measure longitudinal brain activity before, during and after a psychedelic experience, and…

MondayJan 10, 2022 11:11 am

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) to Present at HC Wainwright Bioconnect Virtual Conference

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has announced details regarding its participation at today's HC Wainwright Bioconnect Virtual Conference. The company’s co-founder and CEO Matt Stang will present on Delic’s expansion strategy and industry outlook heading into 2022 and offer one-on-one meetings with investors. Interested parties should visit https://ibn.fm/eTcfl to register for the event, access Delic's presentation and sign up for a one-on-one meeting. To view the full press release, visit https://ibn.fm/oXYCz Delic Holdings Corp. Delic is a leader in new medicines and treatments for a modern…

MondayJan 10, 2022 10:09 am

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Engages JBN Partners LLC, Completes Target-Based Model for AI-Driven Drug Discovery Program

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, has announced its engagement of JBN Partners LLC to increase public awareness of and interest in the company, its management and its products. Under the collaboration, JBN will coordinate certain investor relations and corporate financial public relations with members of the investment community, the financial media and the general public. The services agreement with JBN has a term of six months with a total payment value of $150,000. In addition, the company today announced that it…

FridayJan 07, 2022 11:26 am

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Expanding Presence, Access Within Psychedelic Wellness Space

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, recently sought to expand its presence within psychedelic wellness, entering into a merger agreement with Ketamine Wellness Centers LLC (“KWC”). KWC boasts the nation’s largest chain of psychedelic wellness clinics. A recent article reads, “Under the terms of the deal, Delic agreed to acquire KWC’s chain of 10 ketamine infusion clinics, operating across Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas, and Washington, and merge them with Delic’s existing two ketamine clinics operating under Ketamine Infusions Centers (‘KIC’). Delic now expects to open 15 additional clinics across the country over…

FridayJan 07, 2022 10:57 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes that Adelia Has Reached Milestone Achievement

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced that its wholly owned subsidiary, Adelia Therapeutics Inc., has a achieved a significant milestone. Specific milestones outlined in the Dec. 4, 2021, contribution agreement define what actions are to be taken when certain milestones are reached. When this specific milestone, identified as Year 2 Q1 (v), is reached, the agreement calls for 15,611.4 class B common shares to be issued to Adelia shareholders; those shares are exchangeable for common shares in Cybin capital in accordance with parameters defined by the agreement. Adelia is committed to…

ThursdayJan 06, 2022 2:17 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F) Featured on ‘Gamechangers LIVE’

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, was featured in a recent episode of “Gamechangers LIVE.” The podcast series shines a spotlight on individuals who are gamechangers in their fields and shares perspective on their journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. Joshua Bartch, Mydecine’s co-founder, chairman and CEO, joined the broadcast, hosted by executive coach and speaker Sergio Tigera, to discuss his background as an entrepreneur spanning multiple successful ventures across a variety of industries. Bartch…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

PsychedelicNewsBreaks